Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Novartis AG said on Thursday it had rejected the offer of its US dermatology and nonexclusive pill advantages for India’s Aurobindo Pharma Ltd subsequent to neglecting to get endorsement from a US controller.
Novartis said the choice to end the offer of Sandoz US’s nonexclusive oral solids and dermatology organizations was taken after the organizations didn’t get endorsement from the US Federal Trade Commission inside the foreseen courses of events.
The deal end comes around one and a half years after Novartis said it would sell the benefits for up to $1 billion to Aurobindo under Chief Executive Officer Vas Narasimhan’s arrangements to reshape the drugmaker.
Sandoz will keep on working the benefits as a major aspect of the Sandoz US business, the Swiss pharmaceutical mammoth said.